Standard BioTools Inc.
LAB
$1.01
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.57% | -3.96% | -11.47% | -3.25% | -6.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.57% | -3.96% | -11.47% | -3.25% | -6.61% |
| Cost of Revenue | -17.38% | -7.50% | 1.08% | -8.12% | 34.31% |
| Gross Profit | 57.25% | 0.22% | -21.79% | 2.45% | -46.05% |
| SG&A Expenses | -37.61% | -7.25% | 8.70% | 13.05% | 12.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.22% | -4.31% | 4.00% | 2.80% | -0.48% |
| Operating Income | 61.12% | 4.68% | -21.72% | -9.06% | -5.30% |
| Income Before Tax | 37.78% | 18.10% | -50.91% | 28.04% | -44.18% |
| Income Tax Expenses | 109.24% | -13,310.29% | -1,130.51% | -1,661.54% | -205.31% |
| Earnings from Continuing Operations | 37.42% | 151.16% | -44.55% | 30.54% | -42.47% |
| Earnings from Discontinued Operations | 5,420.84% | 178.01% | 40.17% | 22.14% | 83.10% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 588.10% | 156.59% | -28.77% | 26.81% | 19.04% |
| EBIT | 61.12% | 4.68% | -21.72% | -9.06% | -5.30% |
| EBITDA | 63.81% | -58.34% | -69.40% | -13.71% | -24.28% |
| EPS Basic | 575.73% | 155.05% | -25.10% | 28.42% | 74.12% |
| Normalized Basic EPS | 67.67% | 37.53% | -58.26% | 5.65% | 6.34% |
| EPS Diluted | 575.73% | 155.05% | -25.10% | 28.42% | 74.12% |
| Normalized Diluted EPS | 67.67% | 37.53% | -58.26% | 5.65% | 6.34% |
| Average Basic Shares Outstanding | 2.64% | 2.80% | 2.99% | 2.19% | 28.59% |
| Average Diluted Shares Outstanding | 2.64% | 2.80% | 2.99% | 2.19% | 28.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |